AbBC Therapies

AbBC Therapies is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2020. The company is developing a novel class of antibody biologics that combine antibody targeting with the natural apoptotic enzyme Granzyme B, aiming to overcome limitations of traditional ADCs and checkpoint inhibitors. Its platform is designed to be fully biologic, potentially offering improved safety, efficacy, and manufacturing scalability. The company has a pipeline of seven active programs in oncology and ophthalmology, with two in IND-enabling stages.

Targeted Granzyme B Immunotherapy (TGI) platform: a fully biologic fusion of a tumor-targeting antibody with a human, catalytically active Granzyme B enzyme, designed to deliver potent, immune-like cytotoxicity directly to diseased cells.

AbBC competes in the large and competitive ADC market dominated by companies like AstraZeneca, Pfizer, and Genmab, as well as numerous biotech innovators. Its differentiation is the use of a fully human, biologic Granzyme B payload instead of synthetic toxins, which also places it against other biologic effector platforms (e.g., immunocytokines, engineered toxins).